Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779142 | 0.89 | NPC1 (0.32) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5780239 | 0.86 | PDE10A (0.33) | PDE10A | |
| SCHEMBL5780338 | 0.86 | MAPK14 (0.30) | — | |
| SCHEMBL4769901 | 0.85 | KCNH2 (0.34) | PDE10AALDH1A1SMN1; SMN2 | |
| SCHEMBL5780668 | 0.84 | CYP2A6 (0.38) | ALDH1A1 | |
| SCHEMBL5782435 | 0.83 | AGTR2 (0.34) | ADORA2AADORA1 | |
| SCHEMBL4766440 | 0.82 | BMPR1B (0.33) | — | |
| SCHEMBL5778886 | 0.81 | HCRTR1 (0.31) | ADORA2AADORA1 | |
| SCHEMBL8295703 | 0.81 | PDE4A (0.32) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5783478 | 0.80 | DHODH (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560822-B1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORP (US) | 2006-08-09 | — | — | EP | claimed |
| US-6951864-B2 | 4-imidazol-1-ylmethyl-pyrimidine derivatives | NEUROGEN CORP. (US) | 2005-10-04 | — | — | US | claimed |
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-05-27 | — | — | US | claimed |
| EP-1560822-B1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORP (US) | 2006-08-09 | — | — | EP | disclosed |
| US-6951864-B2 | 4-imidazol-1-ylmethyl-pyrimidine derivatives | NEUROGEN CORP. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1560822-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | Neurogen Corporation (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-05-27 | — | — | US | disclosed |
| WO-2004041808-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES_AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORPORATION (GB) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041808-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES_AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORPORATION (GB) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | GABRA1, GABRA4, GABRA3 | PDE10A 1608/4885TP53 4614/4885GAA 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.